Engelke Carl G, Chinnaiyan Arul M
Michigan Center for Translational Pathology Ann Arbor, MI 48109, USA.
Department of Pathology Ann Arbor, MI 48109, USA.
Cell Res. 2015 Nov;25(11):1187-8. doi: 10.1038/cr.2015.127. Epub 2015 Oct 30.
BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Nature attempt to address this question in acute myeloid leukemia (AML) and independently identify the Wnt signaling pathway as a driver and biomarker of therapeutic resistance.
在过去五年中,BET抑制已成为一种有前景的恶性肿瘤表观遗传疗法,但对于介导敏感性和耐药性之间关系的因素,目前尚未达成共识。最近发表在《自然》杂志上的两篇论文试图在急性髓系白血病(AML)中解决这个问题,并独立确定Wnt信号通路是治疗耐药性的驱动因素和生物标志物。